MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Down – Time to Sell?

MoonLake Immunotherapeutics (NASDAQ:MLTX) gapped down prior to trading on Monday . The stock had previously closed at $18.26, but opened at $17.24. MoonLake Immunotherapeutics shares last traded at $17.1920, with a volume of 1,709,297 shares trading hands.

Key MoonLake Immunotherapeutics News

Here are the key news stories impacting MoonLake Immunotherapeutics this week:

• Positive Sentiment: Strong Phase 3 psoriatic arthritis results: MoonLake said its IZAR-1 trial of sonelokimab met all primary and secondary clinical endpoints at Week 16 in biologic-naïve patients. The 60 mg dose produced an ACR50 response in 42.1% of patients, while ACR20 reached 66.5%; among patients with skin involvement, 61% achieved PASI90. The results strengthen the drug’s prospects and may improve investor confidence in MoonLake’s pipeline. Reuters Phase 3 trial article
• Positive Sentiment: Solid liquidity and upcoming milestones: The company ended the second quarter with $537 million in cash, cash equivalents and short-term investments, expects its cash runway to extend into mid-2028, and has up to $400 million available under its debt facility. Investors are also watching a potential hidradenitis suppurativa BLA submission by the end of September and completion of IZAR-2 enrollment in the third quarter. MoonLake Phase 3 and cash article
• Positive Sentiment: Quarterly loss narrower than expected: MoonLake reported a second-quarter loss of $0.84 per share, better than the analyst consensus loss of $0.92. The earnings beat and increased call-option activity—2,707 calls purchased versus typical daily volume of 1,118—indicate some bullish positioning. Yahoo Finance earnings article
• Neutral Sentiment: Short-interest data is inconclusive: Reported short interest was zero shares with a zero-day days-to-cover ratio, but the stated percentage change was “NaN,” suggesting a data-quality issue rather than a meaningful change in bearish positioning.
• Negative Sentiment: Continued losses and insider selling remain concerns: MoonLake remains unprofitable, with analysts expecting a full-year loss, while company insiders reportedly made 20 sales and no purchases during the past six months. These factors could limit enthusiasm despite the positive trial results.

Analysts Set New Price Targets

Several brokerages have recently weighed in on MLTX. Weiss Ratings reiterated a “sell (e+)” rating on shares of MoonLake Immunotherapeutics in a research note on Friday. Needham & Company LLC boosted their price target on MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, May 12th. BTIG Research reaffirmed a “buy” rating and set a $30.00 price objective on shares of MoonLake Immunotherapeutics in a research note on Tuesday, June 9th. HC Wainwright reaffirmed a “buy” rating and set a $45.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Monday, July 20th. Finally, Leerink Partners lifted their target price on MoonLake Immunotherapeutics from $24.00 to $29.00 and gave the company an “outperform” rating in a research note on Wednesday, July 1st. Ten analysts have rated the stock with a Buy rating, four have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, MoonLake Immunotherapeutics presently has a consensus rating of “Hold” and a consensus price target of $24.21.

MoonLake Immunotherapeutics Trading Down 4.3%

The company has a quick ratio of 8.60, a current ratio of 8.60 and a debt-to-equity ratio of 0.39. The company’s fifty day moving average price is $19.00 and its two-hundred day moving average price is $17.89. The firm has a market cap of $1.22 billion, a PE ratio of -4.32 and a beta of 1.06.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.84) EPS for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.07. As a group, sell-side analysts forecast that MoonLake Immunotherapeutics will post -3.64 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Da Silva Jorge Santos sold 68,289 shares of the company’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $20.02, for a total transaction of $1,367,145.78. Following the transaction, the chief executive officer owned 2,774,893 shares of the company’s stock, valued at $55,553,357.86. This represents a 2.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kristian Reich sold 50,000 shares of the company’s stock in a transaction on Tuesday, July 21st. The stock was sold at an average price of $20.02, for a total transaction of $1,001,000.00. Following the transaction, the insider directly owned 2,714,746 shares in the company, valued at approximately $54,349,214.92. This trade represents a 1.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 344,800 shares of company stock worth $6,820,071. Company insiders own 10.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FNY Investment Advisers LLC purchased a new position in MoonLake Immunotherapeutics in the second quarter valued at about $58,000. Avidity Partners Management LP purchased a new stake in shares of MoonLake Immunotherapeutics during the 1st quarter worth approximately $932,000. Bank of America Corp DE grew its holdings in shares of MoonLake Immunotherapeutics by 5,255.8% in the 1st quarter. Bank of America Corp DE now owns 724,794 shares of the company’s stock worth $13,510,000 after acquiring an additional 711,261 shares during the period. Janus Henderson Group PLC grew its holdings in shares of MoonLake Immunotherapeutics by 64.7% in the 1st quarter. Janus Henderson Group PLC now owns 3,451,628 shares of the company’s stock worth $64,304,000 after acquiring an additional 1,355,640 shares during the period. Finally, EverSource Wealth Advisors LLC increased its stake in MoonLake Immunotherapeutics by 221.1% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,867 shares of the company’s stock valued at $53,000 after purchasing an additional 1,974 shares in the last quarter. 93.85% of the stock is currently owned by institutional investors and hedge funds.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.